Semaglutid , we na wan pawaful mɛrɛsin fɔ lɛf fɔ it bɔku bɔku it ɛn fɔ mɛn pɔsin we gɛt tayp 2 dayabitis, dɔn bi wan pɔpul tritmɛnt we dɛn kin yuz. Wit brand nem dɛm lɛk Wegovy, Ozempic, ɛn Rybelsus, i de gi big wɛlbɔdi bɛnifit.
Insay dis atikul, yu go lan aw fɔ gɛt semaglutide, ilɛksɛf na tru fɔ go to yu pɔsin, fɔ kɔl yu wɛlbɔdi biznɛs na yu fon, ɔ fɔ go na famasi na di intanɛt. Wi go fɛn ɔl di opshɔn dɛm we de fɔ mek shɔ se yu ebul fɔ gɛt dis fayn tritmɛnt sef wan.
Semaglutid dɔn pruv se i fayn fɔ lɔs yu wet bay we i de ridyus di apɛtit, i de delay fɔ ɛmti di bɛlɛ, ɛn i de mek di insulin sekreshɔn bɛtɛ. Dɛn bɛnifit ya kin rili impɔtant fɔ pipul dɛn we gɛt BMI we na 30 ɔ mɔ, ɔ di wan dɛn we gɛt BMI we pas 27 ɔ pas dat we gɛt wɛlbɔdi prɔblɛm bak we gɛt fɔ du wit am lɛk ay blɔd prɛshɔn ɔ tayp 2 dayabitis. Klinik stכdi dεn sho se semaglutide kin mek di bכdi wet fכ di sik pipul dεm we de insay dεn krayteria dεm ya rεdukshכn bכku bכku wan. Dis mɛrɛsin de wok bay we i de falamakata wan natura ɔmon we de ɛp fɔ mek pɔsin angri ɛn di shuga we de na di blɔd.
Semaglutid na impɔtant tin bak fɔ mɛn di tayp 2 dayabitis. Mεdikeshכn dεm lεk Ozempic εn Rybelsus gεt semaglutide, we de wok bay we i de mek insulin prodakshכn na di pankrias εn i de mek di bכdi shuga kכntrכl fayn. Dɛn mɛrɛsin ya kin ɛp bak fɔ ridyus di risk fɔ mek dɛn gɛt prɔblɛm wit dɛn at ɛn blɔd pan pipul dɛn we gɛt dayabitis. as GLP-1 risεptor agonist, semaglutide de εp fכ slo di gastric εmpti, we de kכntribyut fכ impruv glukכs rεguleshכn εn bεtε mεnejmεnt fכ tayp 2 dayabεtis simptom dεm.
Brand Nem fɔ di kɔmni |
Di Praymari Yuz |
FDA Aprɔval Status |
Yuz fɔ Lɔs Wɛt |
Wegovy we de na di wɔl |
We yu de lɔs yu wet |
FDA-apruv fɔ weit lɔs |
Dɛn dɔn gri fɔ mek pɔsin lɔs in wet |
Ozempik we dɛn kɔl |
Tayp 2 dayabitis mɛnejɛmɛnt |
FDA-apruv fɔ dayabitis |
Off-label fɔ mek yu lɔs yu wet |
Raybelsus bin de tɔk bɔt am |
Tayp 2 dayabitis mɛnejɛmɛnt |
FDA-apruv fɔ dayabitis |
Off-label fɔ mek yu lɔs yu wet |
Dɛn kin sɛl Semaglutid ɔnda sɔm brand nem dɛn, ɛn ɛni wan pan dɛn kin du difrɛn tin smɔl. Wegovy na di onli brand we dɔn gɛt FDA aprɔval spɛshal fɔ weit lɔs. Na di ɔda say, dɛn kin yuz Ozempic ɛn Rybelsus mɔ fɔ mɛn tayp 2 dayabitis bɔt bɔku tɛm dɛn kin gi dɛn ɔf-lɛbul fɔ mek pɔsin nɔ gɛt bɔku bɔku bɔdi. Dɛn mɛrɛsin ya dɔn sho se dɛn de wok tranga wan fɔ ridyus di bɔdi wet ɛn kɔntrol di blɔd shuga lɛvɛl, we mek dɛn rili valyu fɔ di wan dɛn we de dil wit ɔl tu di fat ɛn tayp 2 dayabitis.
Fɔ kwalifay fɔ Wegovy (semaglutide) fɔ lɔs dɛn wet, di sikman dɛn fɔ mit patikyula bɔdi mas indeks (BMI) krayteria. Di wan dɛn nid BMI we pas 30 ɔ pas dat (dɛn kin tek am se dɛn fat) ɔ BMI we pas 27 ɔ pas dat wit wan wɛlbɔdi prɔblɛm we gɛt fɔ du wit am lɛk ay blɔd prɛshɔn, tayp 2 dayabitis, ɔ slip apnea. Stɔdi dɔn sho se semaglutide kin mek pɔsin lɔs bɔku bɔku wet, mɔ pan di wan dɛn we de tray tranga wan fɔ lɔs dɛn wet tru tradishɔnal we dɛn nɔmɔ. Dis tritmɛnt dɔn gɛt di aprɔval frɔm di FDA fɔ di wet mɛnejɛmɛnt ɛn bɔku tɛm dɛn kin jɔyn am wit wɛlbɔdi it ɛn ɛksɛsayz rijim.
BMI we gɛt di sik |
Krayteria fɔ Kwalifay |
30+ pipul dɛn |
Kwalifay fɔ lɔs yu wet (we fat pasmak) . |
27+ pipul dɛn |
Kwalifay if wan ɔ mɔr wɛl bɔdi kɔndishɔn wae gɛt fɔ du wit yu wet (ɛgz., haypatɛnshɔn, tayp 2 dayabitis) de |
Dɛn kin gi semaglutid bak fɔ di tayp 2 dayabitis mɛnejɛmɛnt. Di wan dɛn we dɛn no se gɛt tayp 2 dayabitis we nid ɛp fɔ kɔntrol dɛn blɔd shuga lɛvɛl kin fit fɔ gɛt mɛrɛsin lɛk Ozempic ɔ Rybelsus, we dɛn ɔl tu gɛt semaglutide. Di tritmɛnt de ɛp fɔ mek di glycemic kɔntrol bɛtɛ ɛn i de ridyus di risk fɔ gɛt prɔblɛm wit di at ɛn di blɔd.
Di wan dɛn we gɛt BMI we pas 25 ɔ pas dat kin kwalifay fɔ gɛt dɛn mɛrɛsin ya, mɔ we fɔ lɔs dɛn wet na impɔtant pat pan di tritmɛnt plan. Semaglutid kin mek insulin prodyuz ɛn slo di gastric ɛmti, we kin mek i fayn fɔ manej ɔl tu di blɔd shuga ɛn di wet.
Kɔndishɔn |
Fɔ Eligibiliti fɔ Trit |
Tayp 2 Dayabitis |
Ozempic ɔ Rybelsus (wit ɔ atɔl gol fɔ lɔs yu wet) . |
BMI na 25+ |
Kwalifay fɔ Ozempic ɔ Rybelsus |
Sɔntɛnde, wan wan pipul dɛn nɔ kin ebul fɔ gɛt sɛmaglutayd we dɛn kin sɛl bikɔs ɔf di doz we dɛn nid ɔ ɔda rizin dɛn. Kɔmpawnd sɛmaglutayd, we spɛshal famasi dɛn mek, kin bi ɔda we fɔ yuz am. Bɔt, kɔmpawnd sɛmaglutayd nɔ gɛt FDA apruv, ɛn in kwaliti ɛn di we aw i de wok kin difrɛn. Dɛn kin gi dis mɛrɛsin fɔ pipul dɛn we nid spɛshal doz ɔ we gɛt sɛnsitiviti we di standad kɔmɛshɔnal vɛshɔn dɛn nɔ de adrɛs.
Pan ɔl we kɔmpawnd sɛmaglutayd kin mek i ebul fɔ chenj, i kin gɛt mɔ prɔblɛm dɛn, lɛk fɔ gɛt kɔntaminɛshɔn, di we aw dɛn nɔ de tek am di rayt we, ɛn we dɛn nɔ de ɔvasayt di lɔ dɛn. Di wan dɛn we de tink bɔt kɔmpawnd sɛmaglutayd fɔ tɔk bɔt di prɔblɛm ɛn bɛnifit dɛn wit dɛn wɛlbɔdi prɔvayda bifo dɛn go bifo.
Fɔ gɛt semaglutide, ilɛksɛf na fɔ lɔs yu wet ɔ fɔ mɛn yu tayp 2 dayabitis, de fala klia prɔses. Yu kin akses semaglutide tru ɔl tu in-pɔsin kɔnsultɛshɔn, tɛlihɛlth savis, ɔ wan kɔmbaynshɔn fɔ ɔl tu. Na dis na dip luk pan di step dɛm we de insay fɔ gɛt prɛskrishɔn fɔ semaglutide.
Di fɔs tin we yu fɔ du fɔ gɛt semaglutide na fɔ schedul fɔ go to pɔsin we de kia fɔ yu wɛlbɔdi biznɛs. We dɛn de du di in-pɔsin kɔnsultɛshɔn, di dɔktɔ go asɛs yu wɛlbɔdi istri, di mɛrɛsin dɛn we yu de tek naw, ɛn di gol dɛn we yu gɛt fɔ trit yu. Dɛn go ebul fɔ no if semaglutide fayn bay aw yu de sik—ilɛksɛf na fɔ kɔntrol yu wet ɔ di shuga we yu gɛt na yu blɔd. Afta dɛn dɔn luk yu mɛdikal infɔmeshɔn ɛn no if yu fit fɔ gɛt am, di pɔsin we de kia fɔ di wɛlbɔdi biznɛs go rayt wan prɛskrishɔn fɔ semaglutayd.
In-pɔsin visit de gi di bɛnifit fɔ dairekt, kɔmprɛhnsiv kia, usay yu prɔvayda kin asɛs yu wɛlbɔdi bɔdi ɛn adrɛs ɛni kɔnsyusɔn bɛtɛ. Bɔku tɛm, dɛn kin fala dɛn kɔnsultɛshɔn ya, dɛn kin sɛn yu to famasi usay yu kin gɛt di mɛrɛsin we dɛn dɔn gi yu.
Telehɛlth savis dɔn bi wan pɔpul ɛn fayn we fɔ gɛt semaglutide prɛskrishɔn. Bɔku pipul dɛn we de kia fɔ wɛlbɔdi biznɛs naw de gi kɔnsultɛshɔn na di intanɛt, we de mek am izi fɔ di wan dɛn we sik fɔ gɛt mɛrɛsin lɛk semaglutide we dɛn nɔ kɔmɔt na dɛn os.
We yu de du tɛlihɛlth apɔntinmɛnt, yu go kɔmplit wan mɛdikal intake fɔm ɛn sɔntɛm yu go ɔplod di lab rizɔlt dɛn we yu jɔs dɔn. Afta yu dɔn ebul fɔ no yu wɛlbɔdi biznɛs ɛn di tritmɛnt we yu nid, di pɔsin we de kia fɔ yu go gi yu semaglutide if yu mit di mɛdikal krayteria we yu nid. Telehɛlth na wan fayn ɛn aksesbul opshɔn fɔ di wan dɛn we lɛk fɔ kia fɔ dɛn vayrɔyal ɔ we gɛt prɔblɛm fɔ schedul in-pɔsin apɔntinmɛnt.
Ilɛksɛf yu pik fɔ go to yu pɔsin ɔ fɔ go na tɛli wɛlbɔdi kɔnsultɛshɔn, dɛn kin nid fɔ du lab tɛst ɛn wɛlbɔdi asɛsmɛnt fɔ mek shɔ se di sɛmaglutayd fayn fɔ yu wɛlbɔdi kɔndishɔn. Dɛn tɛst ya kin inklud fɔ wach di blɔd shuga lɛvɛl, di kidni wok, ɛn ɔl di mɛtabolik wɛlbɔdi. Fɔ ɛgzampul, if dɛn de gi yu semaglutide fɔ tayp 2 dayabitis, di dɔktɔ kin du tɛst fɔ no aw yu bɔdi de kɔntrol glukɔs fayn fayn wan.
apat frכm dat, dεn de mכnitor di kidni fכ wok εn di tayroyd hεlth, biכs semaglutide kin gεt impak pan dεn כgan dεm ya. Lab test dεm de εp fכ kכnfכm se semaglutide na sef εn ifektiv tritmεnt fכ yu, fכ mek sכh se di mεdikeshכn go bεnεfit εn yu go tכlerεshכn fayn.
Tayp fɔ Tɛst |
Plan |
Di Blɔd Shuga Lɛvɛl |
Fɔ asɛs if yu fit fɔ gɛt prɛskrishɔn we gɛt fɔ du wit dayabitis |
Di Fɔnkshɔn we di Kidni De Du |
I de mek shɔ se yu yuz semaglutide sef wan, mɔ fɔ yuz fɔ lɔng tɛm |
Tayrɔyd Ɛlth |
Impɔtant fɔ di pasɛnt dɛn we de yuz semaglutide fɔ avɔyd tayroyd prɔblɛm |
Fɔ bay semaglutide na di intanɛt kin bi fayn tin, mɔ fɔ di wan dɛn we nɔ ebul fɔ go to wɛlbɔdi biznɛs pɔsin insɛf. Bɔt i impɔtant fɔ mek shɔ se yu de bay frɔm pɔsin we gɛt gud nem fɔ mek shɔ se di mɛrɛsin sef ɛn na tru. Na dis na wetin yu nid fɔ no bifo yu bay semaglutide na di intanɛt.
Bɔku ɔnlayn pletfɔm dɛn de we yu kin abop pan usay yu kin bay semaglutide, bɔt i rili impɔtant fɔ mek shɔ se di famasi we yu pik gɛt laysens ɛn i de fala di FDA standad dɛn. Sɔm ɔnlayn famasi dɛm, lɛk Noom ɛn LifeMD, kin gi tɛlihɛlth kɔnsultɛshɔn, usay di wan dɛm we de kia fɔ wɛlbɔdi biznɛs kin ebul fɔ no aw yu gɛt wɛlbɔdi ɛn dɛn kin gi yu sɛmaglutayd if dɛn si se i fayn. Dɛn de rigul dɛn pletfɔm ya, ɛn dɛn de mek shɔ se yu gɛt di kɔrɛkt mɛrɛsin wit di rayt mɛdikal ovasayt.
Bifo yu bay frɔm ɛni ɔnlayn famasi, chɛk if dɛn gɛt laysens ɛn aks if di famasi rɛjista wit di stet ɔ nashɔnal ɔtoriti dɛn. Dis kin mek shɔ se di mɛrɛsin we yu de gɛt na tru tru mɛrɛsin ɛn di kwaliti we pas ɔl. Bɔku laysens pletfɔm dɛn de gi fri kɔnsultɛshɔn ɛn prɛskrishɔn we pɔsin kin abop pan.
Stej |
Savis dɛn |
Rigyuletɔri Status |
Noom |
Onlayn mɛdikal intake fɔm, weit lɔs program |
Di pɔsin we gɛt laysens fɔ kia fɔ wɛlbɔdi biznɛs |
LayfMD |
Weit lɔs prɛskrishɔn, tɛlihɛlth kɔnsultɛshɔn |
Di pɔsin we gɛt laysens fɔ kia fɔ wɛlbɔdi biznɛs |
Na in yon |
Kompawnd semaglutide, sabskripshɔn plan dɛn |
Famasi we dɛn dɔn rɛjista |
Pan ɔl we fɔ bay semaglutide na di intanɛt kin mek i izi fɔ yu, fɔ bay frɔm say dɛn we nɔ gɛt lɔ, dat kin mek yu gɛt siriɔs prɔblɛm dɛn. Sɔm ɔnlayn famasi dɛn kin sɛl kɔmpitishɔn mɛrɛsin ɔ semaglutide we dɛn nɔ kɔmpawnd fayn we nɔ mit di FDA sefty standad. Dis kin mek yu gɛt bad bad tin dɛn lɛk fɔ yuz di mɛrɛsin di rayt we, fɔ mek yu nɔ klin, ɔ fɔ mek yu nɔ trit yu fayn.
Bɔku tɛm, sɔs dɛn we nɔ gɛt lɔ nɔ nid fɔ gɛt prɛskrishɔn, we kin mek dɛn gɛt mɔ chans fɔ gɛt prɔdak dɛn we denja ɔ we dɛn nɔ chɛk. Apat frɔm dat, kɔmplikɛt sɛmaglutayd kin mek yu gɛt sayd ɛfɛkt lɛk fɔ gɛt prɔblɛm wit yu bɛlɛ, yu at ɛn blɔd prɔblɛm, ɛn ivin prɔblɛm dɛn we kin mek yu layf de pan denja.
Fɔ avɔyd dɛn risk ya, mek shɔ ɔltɛm se di ɔnlayn famasi nid valid prɛskrishɔn frɔm laysens wɛlbɔdi prɔvayda ɛn fala ɔl di rigyuletɔri standad dɛn.
We yu dɔn gɛt prɛskrishɔn, yu kin pik fɔ sɛn am na os. Mek shɔ se yu aks bɔt di tɛm we dɛn de gi di mɛrɛsin ɛn mek shɔ se di mɛrɛsin kɔmɔt frɔm laysens, we dɛn dɔn chɛk.
Brand Nem fɔ di kɔmni |
Prays (Fɔ Wan Mɔnt) . |
Avrej Doz we dɛn kin yuz |
Wegovy we de na di wɔl |
$1,400 fɔ di mɔni |
2,4 mg |
Ozempik we dɛn kɔl |
$1,000 fɔ di mɔni |
2 mg (ɛvri wik) . |
Raybelsus bin de tɔk bɔt am |
$972 |
3 mg (ɛvride) . |
Semaglutid mɛrɛsin lɛk Wegovy ɛn Ozempic kin kɔst bitwin $1,000 ɛn $2,000 fɔ wan mɔnt, i dipen pan di brand ɛn di doz. Fɔ shop rawnd ɛn yuz diskɔnt pletfɔm kin ɛp fɔ mek dɛn kɔst ya smɔl.
Bɔku inshɔrans kɔmni dɛn nɔ kin kɔba semaglutide fɔ mek pɔsin nɔ gɛt bɔku bɔku bɔdi. Bɔt dɛn kin kɔba am fɔ mɛn di sik we dɛn kɔl dayabitis. I impɔtant fɔ chɛk wit yu inshɔrans prɔvayda fɔ si if dɛn kɔba di semaglutide prɛskrishɔn .
Program dɛm lɛk Novo Nordisk in sevings plan kin gi diskɔnt, we kin mek semaglutide mɔ afɔdabul fɔ pasɛnt dɛn we nɔ gɛt inshɔrans kɔvarej.
Semaglutid kin mek yu gɛt sayd ɛfɛkt na yu bɛlɛ lɛk nɔs, vɔmit, ɛn dayarɛa. Dɛn tin ya kin stɔp as di bɔdi de ajɔst.
Semaglutid kin mek yu gɛt mɔ siriɔs tin lɛk pankrias, kidni prɔblɛm, ɛn tayroyd tɔŋ. Di sik pipul dɛn fɔ tɔk bɔt dɛn prɔblɛm ya wit dɛn wɛlbɔdi biznɛs pɔsin.
Pipul wae gɛt histri fɔ tayroyd kansa, pankrias, ɔr kidni prɔblɛm fɔ avɔyd semaglutide. uman dɛn we gɛt bɛlɛ ɔ di wan dɛn we de tray fɔ gɛt bɛlɛ fɔ avɔyd fɔ yuz di mɛrɛsin bak .
Ɔda tin dɛn we yu kin yuz fɔ mek yu gɛt semaglutide na ɔda GLP-1 mɛrɛsin dɛn lɛk liraglutide (Saxenda) ɛn dulaglutide (Trulicity), we kin ɛp bak fɔ mek yu nɔ gɛt bɔku bɔku wet ɛn fɔ kɔntrol di blɔd shuga.
Di chenj na layf stayl lɛk fɔ chenj di it ɛn ɛksesaiz fɔ de wit ɛni tritmɛnt we gɛt mɛrɛsin ɔltɛm. Dɛn we ya we nɔ de tek drɔgs kin ɛp fɔ mek di mɛrɛsin dɛn lɛk semaglutide wok fayn.
Semaglutid kin ple wan impɔtant pat fɔ manej fɔ lɔs yu wet ɔ dayabitis, bɔt fɔ gɛt am nid fɔ mit sɔm patikyula krayteria. Ilɛksɛf na tru in-pɔsin visit, tɛlihɛlth kɔnsultɛshɔn, ɔ ɔnlayn famasi, i impɔtant fɔ mek shɔ se yu gɛt sef ɛn ligal akses. Ɔltɛm, tɔk to pɔsin we de kia fɔ yu wɛlbɔdi biznɛs fɔ no di bɛst we fɔ yu wɛlbɔdi nid.
Cocer PeptidesTM de gi valyu prodak dɛm we de ɛp wan wan pipul dɛm fɔ gɛt semaglutide insay wan sef, rilibul we, we de ɛp dɛn fɔ lɔs dɛn wet ɛn dayabitis mɛnejɛmɛnt joyn.
A: Semaglutid na GLP-1 rεsεpכta agonist we de εp fכ lכs di wet bay we i de sכpres di apεtit εn impruv insulin sεnsitiviti.
A: Yu kin gɛt semaglutide tru pɔsin we de kia fɔ wɛlbɔdi biznɛs, tɛli wɛlbɔdi kɔnsultɛshɔn, ɔ famasi dɛn we gɛt gud nem na di intanɛt.
A: Yu kin kwalifay fɔ gɛt semaglutide if yu mit sɔm patikyula BMI krayteria ɔ yu gɛt wɛlbɔdi prɔblɛm dɛn we gɛt fɔ du wit yu wet lɛk dayabitis.
A: Fɔ bay semaglutide ɔnlayn kin sef if yu pik laysens ɛn rigyuletɛd ɔnlayn famasi dɛn we nid prɛskrishɔn.
A: Di kɔst fɔ semaglutide kin difrɛn, wit di prayz we de frɔm $972 to $1,400 fɔ wan mɔnt dipen pan di brand ɛn di doz.
A: Yes, yu kin akses semaglutide tru pesin ɛp program ɔ pe aut-ɔf-poket fɔ di mɛrɛsin.
